Syneos Health
Syneos Health, a leading biopharmaceutical solutions organisation, is headquartered in the United States and operates extensively across North America, Europe, and Asia. Founded in 2018 through the merger of INC Research and inVentiv Health, the company has quickly established itself as a key player in the clinical research and commercialisation sectors. Specialising in integrated biopharmaceutical solutions, Syneos Health offers a unique combination of clinical development and commercial services, enabling clients to navigate the complexities of drug development more effectively. Their innovative approach and commitment to delivering results have positioned them as a trusted partner for pharmaceutical and biotechnology companies. With a strong market presence, Syneos Health has achieved notable milestones, including recognition for its comprehensive service offerings and a focus on patient-centric solutions, making it a preferred choice in the competitive landscape of biopharmaceutical services.
DitchCarbon Score
How does Syneos Health's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Syneos Health's score of 41 is higher than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Syneos Health's reported carbon emissions
Syneos Health, headquartered in the United States, has made significant commitments to address climate change, although specific carbon emissions data for recent years is currently unavailable. The company has pledged to achieve net zero carbon emissions by 2040, joining over 300 organisations in signing The Climate Pledge. This long-term commitment encompasses all scopes of emissions. In the near term, Syneos Health has set a target to reduce its Scope 1 and 2 emissions by 10% and overall emissions by 5% before 2026. These initiatives reflect the company's proactive approach to minimising its environmental impact and contributing to global sustainability efforts. As part of its strategy, Syneos Health is focused on implementing measures that align with industry standards for climate action, demonstrating a commitment to reducing its carbon footprint in the pharmaceutical and biotechnology sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Syneos Health is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
